David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
David Planchard, MD, PhD
Advertisement
David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.
Articles by David Planchard, MD, PhD
Advertisement
Latest Updated Articles
Standard of Care for EGFR+ ES-NSCLCPublished: October 20th 2020 | Updated:
Practical Implications of ADAURA in NSCLCPublished: October 20th 2020 | Updated:
Molecular Testing in Early-Stage NSCLCPublished: October 20th 2020 | Updated:
Testing for EGFR in NSCLC WorldwidePublished: October 20th 2020 | Updated:
Adjuvant Approaches in EGFR+ NSCLCPublished: October 20th 2020 | Updated:
Clinical Evaluation of ES-NSCLC in JapanPublished: October 20th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5